Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-5635 in NAs-suppressed HBeAg-negative Chronic Hepatitis B
NCT07606950Phase 3Recruiting
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Jul 2026
- Primary completion
- Jun 2028
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
A Phase 3 trial of HRS-5635 in Chronic Hepatitis B (CHB), sponsored by Fujian Shengdi Pharmaceuticals. Started Jul 2026; status: recruiting.
02
Drugs
HRS-5635
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT07606950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07606950.